FINWIRES · TerminalLIVE
FINWIRES

研究快訊:塔爾教育:拓展學習和規模化提升利潤;成長速度將放緩

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下: 好未來教育集團(TAL)公佈2026財年(2月)每股收益為2.75美元(2025財年:0.41美元),高於預期。獲利成長部分得益於其他淨收入的增加(3.47億美元,而2025財年為5,200萬美元),其中包括投資公允價值收益。營收成長34%(2025財年為51%),這主要得益於豐富的學習項目和學習設備,以及對技術整合和人工智慧能力的持續投資。營業利益為2.76億美元(利潤率為9.2%),而2025財年虧損740萬美元(利潤率為-0.3%)。這主要得益於營收成長帶來的規模效益提升,毛利率提高2個百分點至55%,以及銷售、管理及行政費用佔營收的比例下降。 TAL的資產負債表狀況依然穩健,截至2026財年末,淨現金為29億美元,儘管低於2025財年的33億美元。我們預計2027財年至2028財年營收成長將放緩。繼2021年重組後幾年的強勁成長之後,我們認為學習中心網路擴張、線上強化學習計畫成長以及學習設備銷售的成長速度可能會有所放緩。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF